Actemra 162 mg/0.9 ml, Injektionslösung zur subkutanen Anwendung

7680631660014 CH-63166 Injektionslösung zur subkutanen Anwendung
Actemra 162 mg/0.9 ml, Injektionslösung zur subkutanen Anwendung
Actemra 162 mg/0.9 ml, Injektionslösung zur subkutanen Anwendung
Actemra 162 mg/0.9 ml, Injektionslösung zur subkutanen Anwendung
1 / 3
google

Article details

Package size
4
Selling units
4
Measure
Fertigspritze(n)
Galenic form
Injektionslösung zur subkutanen Anwendung
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
03/08/2023
Patient information leaflet
Français
03/08/2023
Patient information leaflet
Italien
03/08/2023

Detailed composition

Substance Quantity Type Category
(N/A)
162.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 1063.70
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/11/2014

Authorization holder

Roche Pharma (Schweiz) AG

4058 Basel

Authorization information

Swissmedic authorization number
63166
Drug name
Actemra, Injektionslösung zur subkutanen Anwendung
Galenic form
LSPA
ATC Code
L04AC07
Authorization status
Z
Dispensing category
A
First authorization
12/09/2014
Authorization expiration date
31/12/9999
IT Number
07.15.0.
Domain
Human medicine
Field of application
Rheumatoide Arthritis, Riesenzellarteriitis, polyartikuläre juvenile idiopathische Arthritis, systemische juvenile idiopatische Arthritis

Package details

Description (FR)
ACTEMRA sol inj 162 mg/0.9 ml ser pré 4 pce
Description (DE)
ACTEMRA Inj Lös 162 mg/0.9 ml Fertspr 4 Stk
Market launch
12/09/2014
Narcotic (BTM)
No